Eledon Pharmaceuticals, Inc. ( (ELDN) ) has released its Q3 earnings. Here is a breakdown of the information Eledon Pharmaceuticals, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies to protect transplanted organs and prevent rejection, as well as to treat amyotrophic lateral sclerosis (ALS), primarily through its lead compound, tegoprubart, an anti-CD40L antibody. The company operates in the biotechnology sector with a focus on immunology and has research and development facilities in Massachusetts, while its corporate headquarters are in California.
In its latest earnings report for the quarter ending September 30, 2025, Eledon Pharmaceuticals reported a net loss of $17.5 million, compared to a net income of $77 million in the same period last year. The company’s cash and cash equivalents decreased significantly to $3.7 million from $20.5 million at the end of 2024, while short-term investments also saw a decline. The company continues to incur significant research and development expenses, which totaled $14.9 million for the quarter.
Key financial highlights include a decrease in total assets from $177.4 million at the end of 2024 to $129.9 million as of September 30, 2025. Operating expenses were primarily driven by the development of tegoprubart, with significant investments in manufacturing and personnel-related costs. The company also reported a change in the fair value of warrant liabilities, contributing to the financial results.
Looking ahead, Eledon Pharmaceuticals remains focused on advancing its clinical trials and product development plans. The company acknowledges the need for additional funding to support its operations and future growth, and it is exploring various financing options. Management is optimistic about the potential of its lead compound and continues to work towards achieving regulatory approvals and commercial success.